Rule 8.1- Neu Tec Pharma PLC

Date : 07/04/2006 @ 5:30AM
Source : UK Regulatory (RNS and others)
Click here for ADVFN's up to the minute news service. Access our extensive collection of financial news from around the world including US, Europe and Asia.
<< Back

 



Rule 8.1- Neu Tec Pharma PLC

RNS Number:6215F
Novartis Pharma AG
04 July 2006


                                                                     FORM 8.1

          DEALINGS BY OFFERORS, OFFEREE COMPANIES OR THEIR ASSOCIATES

                  FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

      (Rules 8.1(a) and (b)(i) of the City Code on Takeovers and Mergers)





1.         KEY INFORMATION


Name of person dealing (Note 1)                Novartis Pharma AG


Company dealt in                               NeuTec Pharma Plc
Class of relevant security to which the        Ordinary shares
dealings being disclosed relate (Note 2)

Date of dealing                                3 July 2006






2.         INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE



(a)        Interests and short positions (following dealing) in the class of
relevant security dealt in (Note 3)


                                                             Long                             
Short


                                               Number                           Number
                                                          (%)                             
(%)

(1) Relevant securities                        2,409,896     8.29%

(2) Derivatives (other than options)


(3) Options and agreements to purchase/sell


Total                                          2,409,896     8.29%





(b)        Interests and short positions in relevant securities of the company,
other than the class dealt in (Note 3)


Class of relevant security:                                  Long                             
Short


                                               Number                           Number
                                                          (%)                             
(%)

(1) Relevant securities


(2) Derivatives (other than options)


(3) Options and agreements to purchase/sell


Total





(c)        Rights to subscribe (Note 3)


Class of relevant security:                    Details









3.         DEALINGS (Note 4)



(a)        Purchases and sales


Purchase/sale                          Number of securities                  Price per unit
(Note 5)


Purchase                               2,000                                 10.40 GBP





(b)        Derivatives transactions (other than options)


Product name,         Long/short (Note 6)       Number of securities (Note 7)        Price per
unit (Note 5)

e.g. CFD










(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying


Product name,         Writing, selling, Number of securities  Exercise   Type, e.g.     
Expiry     Option money
                        purchasing,     to which the option              American,
e.g. call option      varying etc.      relates (Note 7)      price      European etc.   date 
     paid/received per
                                                                                              
     unit (Note 5)







(ii)        Exercising


Product name, e.g. call option         Number of securities                  Exercise price
per unit (Note 5)






(d)        Other dealings (including new securities) (Note 4)


Nature of transaction (Note 8)         Details                               Price per unit
(if applicable) (Note 5)










4.         OTHER INFORMATION



Agreements, arrangements or understandings relating to options or derivatives




Full details of any agreement, arrangement or understanding between the person disclosing and
any other person relating
to the voting rights of any relevant securities under any option referred to on this form or
relating to the voting
rights or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is
referenced.  If none, this should be stated.








Is a Supplemental Form 8 attached? (Note 9)
            NO




Date of disclosure                                                4 July 2006

Contact name                                                      John Manser

Telephone number                                                  00 41 61 324 11 11

Name of offeree/offeror with which associated                     Novartis Pharma AG
Specify category and nature of associate status (Note 10)         N/A







Notes



The Notes on Form 8.1 can be viewed on the Takeover Panel's website at
www.thetakeoverpanel.org.uk




























































                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

DCCSSWFSLSMSEEW
<< Back


Neutec Pharma Plc Historical Chart Neutec Pharma Plc Intraday Chart  
Period
noad


LSE and PLUS quotes are live. NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions :: Contact Us :: Request an Exchange :: Affiliate Scheme
Copyright1999-2008 ADVFN PLC. Copyright and limited reproduction :: Privacy Policy :: Investment Warning :: Advertise with us :: Data accreditations :: Investor Relations :: Press office :: Jobs
ADDITIONAL SERVICES AVAILABLE FROM ADVFN
Upgrade - Click here for more information on ADVFN premium services Money Words - ADVFN Financial Glossary Investor Training ADVFN Financial Bookshop Online Training Academy
31 site:2us 081204 19:03 Stock Message Boards ( 2001 | 2002 | 2003 | 2004 | 2005 | 2005 | 2007 )